Email updates

Keep up to date with the latest news and content from BMC Proceedings and BioMed Central.

This article is part of the supplement: São Paulo Advanced School of Comparative Oncology: Abstracts

Open Access Poster presentation

Identification of genes located at breakpoints of uncharacterized chromosomal translocations by the use of chromosomal microdissection and next generation DNA sequencing

Paulo V Campregher12*, Daniela Borri1, Patrícia Severino1, Natália Torres1, Elvira RP Velloso1, Nelson Hamerschlak1 and Fernando F Costa2

Author Affiliations

1 Albert Einstein Hospital Research Institute, São Paulo, Brazil

2 Faculdade de Ciências Médicas - Universidade Estadual de Campinas, Campinas, Brazil

For all author emails, please log on.

BMC Proceedings 2013, 7(Suppl 2):P55  doi:10.1186/1753-6561-7-S2-P55

The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1753-6561/7/S2/P55


Published:4 April 2013

© 2013 Campregher et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background

Cancer results from accumulation of pathogenic genetic changes in a somatic cell. Chromosomal translocations (CT) are among the most common molecular changes associated with the development of cancer. The mechanism by which CT causes cancer is through the juxtaposition of two genes, generating a hybrid protein with oncogenic function or through the placing of a proto-oncogene under the control of a promoter region active in the cell of origin. While most genes located at the breakpoints of common CT have been identified, several, less frequent, CT remain uncharacterized.

Materials and methods

We propose to study a cohort of 17 already identified patients with hematologic malignancies that have uncharacterized CT in the neoplastic cells. To accomplish that, we will perform CT microdissection followed by amplification of chromosomal DNA, and DNA sequencing using next generation DNA sequencing.

Results

As a pilot study, we have performed microdissection and amplification of a normal chromosome 7, and tested the efficacy of the entire process by doing a PCR for the BRAF gene, which is located on chromosome 7. PCR amplification yielded a specific band with the right molecular weight, attesting the success of our method. In addition, we have successfully microdissected uncharacterized CT of 8 patients, and successfully amplified the DNA of two of these cases.

Conclusion

We are developing a platform for rapid and robust identification of genes present at breakpoints of uncharacterized CTs, and will identify genes involved in CT of 17 patients with hematological malignancies.

Financial support

Hospital Albert Einstein.